[Studies of gastric motility with endoscopic 8mm cinematography. 2. Gastric motility following selective proximal vagotomy].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M Kamiyama.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Growth inhibition or stimulation of target adenocarcinoma cells in rats sensitized with spleen cells from syngeneic tumor-bearing rats was significantly suppressed in colony inhibition assays when the spleen cells were treated in vitro with 0.8 mug progesterone or more/ml medium. In addition, when tumor-bearing rats were treated with 1 mg medroxyprogesterone acetate weekly in vivo, the inhibiting action of the spleen cells from rats with regressed tumors was also suppressed. Progesterone thus suppressed immune spleen cells in vivo and in vitro.
Transplantable cloned HTP/Cl culture was a stable line derived from a rat uterine adenocarcinoma that was induced by 7,12-dimethylbenz(a)anthracene in vivo and did not display density-dependent inhibition of growth. This HTP/Cl culture easily adapted to grow in a culture medium containing progesterone, 8 mug/ml. As compared with HTP/Cl culture, HTP/Cl/P8 culture grown in the presence of progesterone was contact inhibited, and a cellular differentiation was observed in the tumor tissues that developed after inoculation of cells. These actions of progesterone on uterine adenocarcinoma cells were completely reversible on removal of the hormone in vitro. These results appeared to indicate that progesterone was involved in the regulation of both cellular proliferation and differentiation. The possible mechanisms of the regulation of rat uterine adenocarcinoma cells by progesterone are discussed in relation to cellular levels of cyclic adenosine 3':5'-monophosphate in vitro.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.